Medinger M, Drexler B, Lengerke C, Passweg J. Pathogenesis of acquired aplastic anemia and the role of the bone marrow microenvironment. Front Oncol. 2018;8:587.

Article  PubMed  PubMed Central  Google Scholar 

Peslak SA, Olson T, Babushok DV. Diagnosis and treatment of aplastic anemia. Curr Treat Options Oncol. 2017;18:70.

Article  PubMed  PubMed Central  Google Scholar 

Young NS. Aplastic anemia. N Engl J Med. 2018;379:1643–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2015;172:187–207.

Article  PubMed  Google Scholar 

Frickenhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101:1236–42.

Article  Google Scholar 

Tichelli A, Schrezenmeier H, Socié G, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2011;117:4434–41.

Article  CAS  PubMed  Google Scholar 

Rosenfeld S, Vollmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia. JAMA. 2003;289:1130–5.

Article  CAS  PubMed  Google Scholar 

Scheinberg P, Wu CO, Nunez O, et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica. 2009;94:348–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Promacta. Package insert. Novartis Pharmaceuticals Corporation; 2021.

Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376:1540–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al. Eltrombopag added to immunosuppression in severe aplastic anemia N Engl J Med. 2022;386:11–23. https://doi.org/10.1056/NEJMoa2109965.

Zaimoku Y, Patel BA, Shalhoub R, et al. Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag. Haematologica 2021 [Online ahead of print].

Kadia T, Ravandi F, Daver N, et al. Single-center experience of immunosuppressive therapy with or without eltrombopag in patients with aplastic anemia. Blood. 2015;126:4779.

Article  Google Scholar 

Assi R, Garcia-Manero G, Ravandi F, et al. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018;124:4192–201.

Article  CAS  PubMed  Google Scholar 

Fang M, Song H, Zhang J, Li S, Shen D, Tang Y. Efficacy and safety of immunosuppressive therapy with or without eltrombopag in pediatric patients with acquired aplastic anemia: a Chinese retrospective study. Pediatr Hematol Oncol J 2021 [Online ahead of print].

Lesmana H, Jacobs T, Boals M, et al. Eltrombopag in children with severe aplastic anemia. Pediatr Blood Cancer. 2021;68: e29066.

Article  CAS  PubMed  Google Scholar 

Jie M, Fu L, Li S, et al. Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children. Pediatr Hematol Oncol J 2021 [Online ahead of print].

Hwang Y, Gill H, Chan TSY, et al. Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting. Hematol. 2018;23:399–404.

Article  CAS  Google Scholar 

Boddu P, Garcia-Manero G, Ravandi F, et al. Clinical outcomes in adult patients with aplastic anemia: a single institution experience. Am J Hematol. 2017;92:1295–302.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Imada K, Obara N, Iida H, et al. Eltrombopag in combination with rabbit anti-thymocyte globulin/cyclosporine A in immunosuppressive therapy-naïve patients with aplastic anemia in Japan. Intern Med. 2021;60:1159–68. https://doi.org/10.2169/internalmedicine.6063-20.

Article  CAS  PubMed  Google Scholar 

Groarke EM, Patel BA, Gutierrez-Rodrigues F, et al. Eltrombopag added to immunosuppression for children with treatment-naïve severe aplastic anemia. Br J Haematol. 2021;192:605–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kao SY, Xu W, Brandwein JM, et al. Outcomes of older patients (>60 years) with acquired aplastic anaemia treated with immunosuppressive therapy. Br J Haematol. 2008;143:738–43.

Article  PubMed  Google Scholar 

Common Terminology Criteria for Adverse Events (CTCAE) v5.0. National Cancer Institute: Division of Cancer Treatment & Diagnosis;2018. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf. Accessed June 11, 2022.

Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129:1428–36.

Article  CAS  PubMed  Google Scholar 

Pritz T, Weinberger B, Grubeck-Lobenstein B. The aging bone marrow and its impact on immune responses in old age. Immunol Lett. 2014;162:310–5.

Article  CAS  PubMed  Google Scholar 

Zaimoku Y, Patel BA, Shalhoub R, et al. Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag. Haematologica. 2022;107:126–33.

Article  CAS  PubMed  Google Scholar